Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome
Crossref DOI link: https://doi.org/10.1007/s00381-017-3690-9
Published Online: 2017-12-13
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Abu Arja, Mohammad H.
Conley, Suzanne E.
Salceda, Violeta
Al-Sufiani, Fahd
Boué, Daniel R.
Finlay, Jonathan L.
License valid from 2017-12-13